Drugs / Patidegib
Patidegib
also known as
IPI-926 · FIN-5 · FIN-6 HYDROCHLORIDE · IP-9 HYDROCHLORIDE · IP9 FREE BASE · IPI-926 FREE BASE · IPI-926 hydrochloride · PATIDEGIB HYDROCHLORIDE · +1 more
Small molecule targets SMO via inhibition
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01383538 | Aug 2011 → Dec 2012 | adenocarcinoma, malignant pancreatic neoplasm | Andrew Ko | Completed | No outcome recorded |
| Phase 1 | NCT01255800 | Apr 2011 → Dec 2013 | head and neck cancer | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 1 | NCT00761696 | Sep 2008 → Apr 2012 | neoplasm | Infinity Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT04155190 | Dec 2019 → Apr 2021 | basal cell carcinoma | Sol-Gel Technologies, Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT02828111 | Nov 2016 → Nov 2017 | basal cell carcinoma | PellePharm, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02762084 | Jun 2016 → Apr 2017 | nevoid basal cell carcinoma syndrome | PellePharm, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01371617 | Oct 2011 → Aug 2012 | myelofibrosis, primary myelofibrosis | Infinity Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06050122 | Mar 2024 → Aug 2026 overdue | nevoid basal cell carcinoma syndrome | Sol-Gel Technologies, Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04308395 | Jun 2020 → Jul 2021 | nevoid basal cell carcinoma syndrome | Sol-Gel Technologies, Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT03703310 | Feb 2019 → Dec 2020 | nevoid basal cell carcinoma syndrome | Sol-Gel Technologies, Ltd. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01609179 | Mar → Oct 2012 | basal cell carcinoma, chondrosarcoma | Infinity Pharmaceuticals, Inc. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01130142 Comparator | Apr 2010 → May 2012 | malignant pancreatic neoplasm | Infinity Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01310816 Comparator | Feb 2011 → Nov 2013 | chondrosarcoma | Infinity Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Patidegib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06050122 ↗ |
| Known as | FIN-5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL538867 ↗ |
| Known as | FIN-6 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL538867 ↗ |
| Known as | IP-9 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL538867 ↗ |
| Known as | IP9 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL538867 ↗ |
| Known as | IPI-926 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01255800 ↗ |
| Known as | IPI-926 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL538867 ↗ |
| Known as | IPI-926 hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL538867 ↗ |
| Known as | PATIDEGIB HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL538867 ↗ |
| Known as | Saridegib | ChEMBL registry synonym — accepted as the source's own label CHEMBL538867 ↗ |
| Action | Inhibit | “Hedgehog pathway inhibitor” NCT00761696 ↗ |
| Modality | Small molecule | — CHEMBL538867 ↗ |
| Route | Oral | “Oral daily dosing” NCT00761696 ↗ |
| Target | SMO | “a potent and specific antagonist of the Hh pathway that binds Smoothened (Smo)” NCT01383538 ↗ |